Trial record 1 of 1 for: millennium C25003
Previous Study | Return to List | Next Study
Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma
This study is ongoing, but not recruiting participants.
Millennium Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Information provided by (Responsible Party):
Takeda ( Millennium Pharmaceuticals, Inc. )
First received: October 19, 2012
Last updated: July 31, 2017
Last verified: July 2017
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||March 1, 2020|
|Primary Completion Date:||April 20, 2017 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Epub 2013 Nov 15.